Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


New funding opportunities for UCL researchers seeking to develop impact from research in EPSRC remit

6 December 2012

As highlighted in the Provost’s Newsletter of 4 December 2012 new opportunities for funding are available from UCL Enterprise.

The new schemes include Discovery to Use and Secondments funding. More information about these and other schemes can be also found here (this page requires a UCL login).